📊 CORT Key Takeaways
Is Corcept Therapeutics Inc. (CORT) a Good Investment?
Revenue is growing at 12.8% YoY with healthy 51.2% gross margins, but the company is deeply unprofitable with operating losses of $49.6M and negative free cash flow of $17.0M, indicating unsustainable cash burn despite a strong balance sheet providing runway.
Corcept shows solid fundamental durability through double-digit revenue growth, strong free cash flow generation, and a debt-free balance sheet with ample liquidity. However, growth quality is mixed because net income is nearly flat versus revenue growth, diluted EPS fell sharply year over year, and reported gross/operating margins are thin for the revenue base. The company looks financially healthy, but margin conversion and per-share earnings performance need to improve to support a more bullish fundamental view.
Why Buy Corcept Therapeutics Inc. Stock? CORT Key Strengths
- Revenue growth of 12.8% YoY demonstrates market demand and business traction
- Strong gross margins of 51.2% show healthy core product economics
- Fortress balance sheet with $108.7M cash, zero debt, and 2.86x current ratio provides 6+ years of runway
- Debt-free balance sheet with strong liquidity and $120.50M in cash
- Healthy cash generation with $142.00M operating cash flow and $141.78M free cash flow
- Revenue growth remains solid at 12.8% YoY with positive ROE and ROA
CORT Stock Risks: Corcept Therapeutics Inc. Investment Risks
- Negative free cash flow of $17.0M annually is structurally unsustainable long-term
- Operating margin of -30.1% shows severe inability to control operating expenses relative to revenue
- EPS declining 33.3% YoY indicates worsening profitability trajectory despite revenue growth
- Diluted EPS declined 33.3% YoY despite higher revenue, indicating weak per-share earnings quality
- Net income growth of only 1.5% lags revenue growth, suggesting margin pressure or rising costs
- Reported gross margin of 11.1% and operating margin of 5.9% leave limited cushion if expenses rise
Key Metrics to Watch
- Quarterly operating cash flow trend and timeline to breakeven
- Operating expense ratio relative to revenue growth rate
- Cash balance and burn rate sustainability vs. 5-year runway
- Operating and gross margin trend
- Diluted EPS growth versus revenue growth
Corcept Therapeutics Inc. (CORT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.86x current ratio provides a solid financial cushion.
CORT Profit Margin, ROE & Profitability Analysis
CORT vs Healthcare Sector: How Corcept Therapeutics Inc. Compares
How Corcept Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Corcept Therapeutics Inc. Stock Overvalued? CORT Valuation Analysis 2026
Based on fundamental analysis, Corcept Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Corcept Therapeutics Inc. Balance Sheet: CORT Debt, Cash & Liquidity
CORT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Corcept Therapeutics Inc.'s revenue has grown significantly by 108% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.94 reflects profitable operations.
CORT Revenue Growth, EPS Growth & YoY Performance
CORT Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $157.2M | $20.5M | $0.17 |
| Q3 2025 | $182.5M | $19.7M | $0.16 |
| Q2 2025 | $163.8M | $20.5M | $0.29 |
| Q1 2025 | $146.8M | $20.5M | $0.17 |
| Q3 2024 | $123.6M | $15.9M | $0.28 |
| Q2 2024 | $117.7M | $15.9M | $0.25 |
| Q1 2024 | $105.7M | $15.9M | $0.14 |
| Q3 2023 | $101.7M | $15.9M | $0.28 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Corcept Therapeutics Inc. Dividends, Buybacks & Capital Allocation
CORT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Corcept Therapeutics Inc. (CIK: 0001088856)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CORT
What is the AI rating for CORT?
Corcept Therapeutics Inc. (CORT) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CORT's key strengths?
Claude: Revenue growth of 12.8% YoY demonstrates market demand and business traction. Strong gross margins of 51.2% show healthy core product economics. ChatGPT: Debt-free balance sheet with strong liquidity and $120.50M in cash. Healthy cash generation with $142.00M operating cash flow and $141.78M free cash flow.
What are the risks of investing in CORT?
Claude: Negative free cash flow of $17.0M annually is structurally unsustainable long-term. Operating margin of -30.1% shows severe inability to control operating expenses relative to revenue. ChatGPT: Diluted EPS declined 33.3% YoY despite higher revenue, indicating weak per-share earnings quality. Net income growth of only 1.5% lags revenue growth, suggesting margin pressure or rising costs.
What is CORT's revenue and growth?
Corcept Therapeutics Inc. reported revenue of $164.9M.
Does CORT pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
Where can I find CORT SEC filings?
Official SEC filings for Corcept Therapeutics Inc. (CIK: 0001088856) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CORT's EPS?
Corcept Therapeutics Inc. has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CORT a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Corcept Therapeutics Inc. has a SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CORT stock overvalued or undervalued?
Valuation metrics for CORT: ROE of -5.0% (sector avg: 15%), net margin of -19.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy CORT stock in 2026?
Our dual AI analysis gives Corcept Therapeutics Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CORT's free cash flow?
Corcept Therapeutics Inc.'s operating cash flow is $-16.8M, with capital expenditures of $201.0K. FCF margin is -10.3%.
How does CORT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -19.3% (avg: 12%), ROE -5.0% (avg: 15%), current ratio 2.86 (avg: 2).